Compare JFU & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | BRNS |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 55.9M |
| IPO Year | 2018 | 2021 |
| Metric | JFU | BRNS |
|---|---|---|
| Price | $4.35 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 2.6K | ★ 54.7K |
| Earning Date | 01-01-0001 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.56 |
| 52 Week High | $9.48 | $2.91 |
| Indicator | JFU | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 49.12 |
| Support Level | $4.24 | $0.56 |
| Resistance Level | $5.66 | $0.76 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 9.79 | 68.74 |
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.